PE20081531A1 - Nuevos compuestos 620 - Google Patents

Nuevos compuestos 620

Info

Publication number
PE20081531A1
PE20081531A1 PE2008000008A PE2008000008A PE20081531A1 PE 20081531 A1 PE20081531 A1 PE 20081531A1 PE 2008000008 A PE2008000008 A PE 2008000008A PE 2008000008 A PE2008000008 A PE 2008000008A PE 20081531 A1 PE20081531 A1 PE 20081531A1
Authority
PE
Peru
Prior art keywords
imidazol
cycloalkyl
aryl
phenyl
amino
Prior art date
Application number
PE2008000008A
Other languages
English (en)
Inventor
Stefan Berg
Sofia Karlstrom
Karin Kolmodin
Johan Lindstrom
Jan-Erik Nystrom
Fernando Sehgelmeble
Peter Soderman
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Publication of PE20081531A1 publication Critical patent/PE20081531A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUILO C3-C6, ARILO, ENTRE OTROS; B ES ARILO, HETEROARILOOPCIONALMENTE SUSTITUIDOS POR R6; C ES ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDOS POR UNO O MAS R7; R1 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R1, R2, R3 Y R4 SON CADA UNO Si(R8)3; R5, R6 Y R7 SON CADA UNO HALOGENO, NITRO, CHO, ENTRE OTROS; m, n Y p SON CADA UNO 0-3. SON COMPUESTOS PREFERIDOS: 2-AMINO-5-(3'-METOXIBIFENIL-3-IL)-3-METIL-5-[4-(TRIMETILSILIL)FENIL]-3,5-DIHIDRO-4H-IMIDAZOL-4-ONA; SAL DE ACIDO ACETICO DE 2-AMINO-5-[3-(5-FLUOROPIRIDIN-3-IL)FENIL]-3-METIL-5-(4-TRIMETILSILILFENIL)IMIDAZOL-4-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE SINDROME DE DOWN, ANGIOPATIA BETHA AMILOIDE, ALZHEIMER, ENTRE OTROS
PE2008000008A 2006-12-20 2008-01-02 Nuevos compuestos 620 PE20081531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87095306P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081531A1 true PE20081531A1 (es) 2008-12-12

Family

ID=39536554

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000008A PE20081531A1 (es) 2006-12-20 2008-01-02 Nuevos compuestos 620

Country Status (4)

Country Link
US (1) US20080161269A1 (es)
PE (1) PE20081531A1 (es)
TW (1) TW200831484A (es)
WO (1) WO2008076045A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
AR056865A1 (es) * 2005-06-14 2007-10-31 Schering Corp Heterociclos nitrogenados y su uso como inhibidores de proteasas, composiciones farmaceuticas
AR061264A1 (es) * 2006-06-12 2008-08-13 Schering Corp Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih.
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
JP2011518224A (ja) * 2008-04-22 2011-06-23 シェーリング コーポレイション Ｂａｃｅ−１阻害剤としてのチオフェニル置換２−イミノ−３−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
CN101337866B (zh) * 2008-08-12 2010-12-29 苏州大学 一种催化氧化炔烃制备1,2-二酮的方法
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
DK2406240T3 (en) 2009-03-13 2016-02-01 Vitae Pharmaceuticals Inc INHIBITORS OF BETA-secretase
UY32750A (es) * 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
AR077447A1 (es) * 2009-07-02 2011-08-31 Astrazeneca Ab Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas
CN101624322B (zh) * 2009-08-05 2012-07-18 苏州大学 一种催化氧化炔烃制备1,2-二酮的方法
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2747769B1 (en) 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG163508A1 (en) * 2003-12-15 2010-08-30 Schering Corp Heterocyclic aspartyl protease inhibitors
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
WO2006138217A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
MX2007016185A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos.
AU2006266167A1 (en) * 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
US7763606B2 (en) * 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1943246A1 (en) * 2005-10-31 2008-07-16 Schering Corporation Aspartyl protease inhibitors

Also Published As

Publication number Publication date
WO2008076045A1 (en) 2008-06-26
US20080161269A1 (en) 2008-07-03
TW200831484A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
PE20081531A1 (es) Nuevos compuestos 620
CY1123578T1 (el) Ισοξαζολινες ναφθαλενιου ως παραγοντες καταπολεμησης ασπονδυλων επιβλαβων οργανισμων
PE20081530A1 (es) Nuevos compuestos 617
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
AR061644A1 (es) Derivados de benzofurano
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
EA201170096A1 (ru) Замещенные производные пиримидона
PH12016502154A1 (en) Pyridazonine herbicides
TN2012000033A1 (en) Mixtures of mesoionic pesticides
JO2668B1 (en) Isoczazolins for controlling invertebrate insects
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
MY142807A (en) Benzimidazole derivative and use thereof.
PE20170444A1 (es) Herbicidas de piperidinona
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
PE20090708A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
PE20142400A1 (es) Compuestos novedosos
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20140102A1 (es) Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
AR049438A1 (es) Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
PE20091490A1 (es) Derivados sustituidos de indol
PE20120063A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3

Legal Events

Date Code Title Description
FD Application declared void or lapsed